Figure 1: Nucleotide and Amino Acid Sequences

CDRH1: GFTFSDYNMA (SEQ ID NO:1)
CDRH2: TITYEGRNTYYRDSVKG (SEQ ID NO:2)
CDRH3: PPQYYEGSIYRLWFAH (SEQ ID NO:3)
CDRL1: RADESVTTLMH (SEQ ID NO:4)
CDRL2: LVSNRES (SEQ ID NO:5)
CDRL3: QQTWSDPWT (SEQ ID NO:6)

CDRL1 for CA028_496.g3: RADESVRTLHM (SEQ ID NO:7)
CDRL2 for CA028_496.g3: LVSNSEI (SEQ ID NO:8)

Light Chain variable region of antibody CA028_496 (gL7)(SEQ ID NO:9)
AIQLTQSPSSLSASVGDRVTITCRADESVTTLMHWYQQKPGKAPKLLIYLVSNRESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQTWSDPWTFGQ
GTKVEIKR

Light Chain variable region of antibody CA028_496.g3 (gL57) (SEQ ID NO:10)
AIQLTQSPSSLSASVGDRVTITCRADESVRTLMHWYQQKPGKAPKLLIYLVSNSEIGVPDRFSGSGSGTDFRLTISSLQPEDFATYYCQQTWSDPWTFGQ
GTKVEIK

Heavy Chain variable region of antibody CA028_496 and CA028_496.g3 (gH9)(SEQ ID NO:11)
EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYNMAWVRQAPGKGLEWVATITYEGRNTYYRDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCASPP
QYYEGSIYRLWFAHWGQGTLVTVSS

Light chain of antibody CA028_496 (without signal) (SEQ ID NO:12)
AIQLTQSPSSLSASVGDRVTITCRADESVTTLMHWYQQKPGKAPKLLIYLVSNRESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQTWSDPWTFGQ
GTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQG
LSSPVTKSFNRGEC

Light chain of antibody CA028 496.g3 (without signal) (SEQ ID NO:13)

AIQLTQSPSSLSASVGDRVTITCRADESVRTLMHWYQQKPGKAPKLLIYLVSNSEIGVPDRFSGSGSGTDFRLTISSLQPEDFATYYCQQTWSDPWTFGQ
GTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQG
LSSPVTKSFNRGEC

Light chain of antibody CA028 496.g3 including signal (SEQ ID NO:14)

MSVPTQVLGLLLLWLTDARCAIQLTQSPSSLSASVGDRVTITCRADESVRTLMHWYQQKPGKAPKLLIYLVSNSEIGVPDRFSGSGSGTDFRLTISSLQP
EDFATYYCQQTWSDPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT
LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

Heavy chain of antibody CA028 496 SEQ ID NO:15)

EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYNMAWVRQAPGKGLEWVATITYEGRNTYYRDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCASPP
QYYEGSIYRLWFAHWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSS
LGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQ
FNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTP
PVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK

Heavy chain of antibody CA028 496.g3 (without signal) (SEQ ID NO:16)

EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYNMAWVRQAPGKGLEWVATITYEGRNTYYRDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCASPP
QYYEGSIYRLWFAHWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSS
LGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPR
EEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK
TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

Heavy chain of antibody CA028 496.g3 including signal (SEQ ID NO:17)

MEWSWVFLFFLSVTTGVHSEVQLVESGGGLVQPGGSLRLSCAASGFTFSDYNMAWVRQAPGKGLEWVATITYEGRNTYYRDSVKGRFTISRDNAKNSLYL
QMNSLRAEDTAVYYCASPPQYYEGSIYRLWFAHWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAV
LQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEV
KFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFY
PSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

DNA encoding Light Chain variable region of antibody CA028 496.g3 (SEQ ID NO:18)

gccatccagctgacccagagcccttcctctctcagcgccagtgtcggagacagagtgactattacctgcagggctgacgaaagcgtgagaacattgatgc
actggtaccaacagaagcctggcaaagccccaagctcctgatctatctggtttccaattcggagattggagtccccgacaggttcagcggcagtgggtc
tggaactgactttcgcctgacaatctcctcactccagcccgaagatttcgccacctactattgccagcagacttggagcgacccttggacatttggacag
ggcacaaaagtggagatcaag

DNA encoding Heavy Chain variable region of antibody CA028_496 and CA028_496.g3 (SEQ ID NO:19)

gaggttcagctcgttgaatccggaggcggactcgtgcagcctgggggctccttgcggctgagctgcgctgccagtggcttcactttcagcgattacaata
tggcctgggtgcgccaggccccaggcaagggtctggagtgggtggccacaattacctatgagggcagaaacacttattaccgggattcagtgaaagggcg
atttaccatcagcagggataatgcaaagaacagtctgtacctgcagatgaactctctgagagctgaggacaccgctgtctactattgtgcaagcccaccc
cagtactatgagggctcaatctacagattgtggtttgcccattggggccagggaacactggtgaccgtctcgagc

DNA encoding light chain of antibody CA028 496 including signal sequence (SEQ ID NO:20)

Atgtcagttcccacacaggtgctgggcctgcttctgttgtggctcaccgatgctaggtgtgccatccagctgacccagagcccttcctctctcagcgcca
gtgtcggagacagagtgactattacctgcagggctgacgaaagcgtgaccacattgatgcactggtaccaacagaagcctggcaaagcccccaagctcct
gatctatctggtttccaatcgggagtctggagtccccagcaggttcagcggcagtgggtctggaactgactttaccctgacaatctcctcactccagccc
gaagatttcgccacctactattgccagcagacttggagcgacccttggacatttggacagggcacaaaagtggagatcaagcgtacggtagcggccccat
ctgtcttcatcttcccgccatctgatgagcagttgaaatctggaactgcctctgttgtgtgcctgctgaataacttctatcccagagaggccaaagtaca
gtggaaggtggataacgccctccaatcgggtaactcccaggagagtgtcacagagcaggacagcaaggacagcacctacagcctcagcagcaccctgacg
ctgagcaaagcagactacgagaaacacaaagtctacgcctgcgaagtcacccatcagggcctgagctcgcccgtcacaaagagcttcaacaggggagagt
gttag

DNA encoding light chain of antibody CA028 496.g3 (no signal sequence) (SEQ ID NO:21)

gccatccagctgacccagagcccttcctctctcagcgccagtgtcggagacagagtgactattacctgcagggctgacgaaagcgtgagaacattgatgc
actggtaccaacagaagcctggcaaagccccaagctcctgatctatctggtttccaattcggagattggagtccccgacaggttcagcggcagtgggtc
tggaactgactttcgcctgacaatctcctcactccagcccgaagatttcgccacctactattgccagcagacttggagcgacccttggacatttggacag
ggcacaaaagtggagatcaagcgtacggtagcggccccatctgtcttcatcttcccgccatctgatgagcagttgaaatctggaactgcctctgttgtgt
gcctgctgaataacttctatcccagagaggccaaagtacagtggaaggtggataacgccctccaatcgggtaactcccaggagagtgtcacagagcagga
cagcaaggacagcacctacagcctcagcagcaccctgacgctgagcaaagcagactacgagaaacacaaagtctacgcctgcgaagtcacccatcagggc
ctgagctcgcccgtcacaaagagcttcaacaggggagagtgttag

DNA encoding light chain of antibody CA028 496.g3 including signal sequence (SEQ ID NO:22)

atgtcagttcccacacaggtgctgggcctgctcttctgttgtggccatccagctgacccagagcccttcctctcagcgcca
gtgtcggagacagagtgactattacctgcagggctgacgaaagcgtgagaacattgatgcactggtaccaacagaagcctggcaaagcccccaagctcct
gatctatctggtttccaattcgggagattggagtcccgacaggttcagcggcagtgggtctggaactgacttcgcctgacaatctcctcactccagccc
gaagatttcgccacctactattgccagcagacttggacacagggcacacaaaagtggagatcaagcgtacggtagcggccccat
ctgtcttcatcttcccgccatctgatgagcagttgaaatctggaactgcctctgttgtgtgcctgctgaataacttctatcccagagaggccaaagtaca
gtggaaggtggataacgccctccaatcgggtaactcccaggagagtgtcacagagcaggacaaggcaggacacctacagcctcagcagcaccctgacg
ctgagcaaagcagactacgagaaacacaaagtctacgcctgcgaagtcacccatcagggcctgagctcgcccgtcacaaagagcttcaacagggggagagt
gttag

DNA encoding heavy chain of antibody CA028 496 (including signal sequence) (SEQ ID NO:23)

atggaatggtcctgggtcttcctgttttccttttctgtcacaaccgggtgcacagcgaggttcagctcgttgaatccggaggcggactcgtgcagcctg
gggggctccttgcggctgagctgcgctgccagtggcttcactttcagcgatttacaatatggcctgggtgcgccaggcccaggcaagggtctggagtgggt
ggccacaattacctatgagggcagaaacacttattaccgggatttcagtgaaagggcgatttaccatcagcagggataatgcaaagaacagtctgtacctg
cagatgaactctctgagagctgaggacaccgctgtctactattgtgcaagcccaccccagtactatgagggctcaatctacagattgtggtttgcccatt
ggggccagggaacactggtgaccgtctcgagcgcttctacaaagggcccatccgtcttccccctggcgccctcctgcaggagcacctccgagagcacagc
cgccctgggctgcctggtcaaggactacttccccgaaccggtgtcgtggaactcaggcgccctgaccagcggcgtgcacaccttcccggctgtc
ctacagtcctcaggactctactccctcagcagcgtggtgaccgtgccctccagcagcttgggcacgaagacctacacctgcaacgtagatcacaagccca
gcaacaccaaggtggacaagagagttggtgagaggccagcacagggagggagggtgtctgctggaagccaggctcagcccctcctgcctggacgcaccccg
gctgtgcagccccagcccagggcagcaaggcatgccccatctgtctcctcacccggaggcctctgaccagcccaccccactcatgcccagggagagggtcttctg
gatttttccaccaggctccgggcagccacaggctggatgcccctacccaggccctgcgctgcgctcagacctgccaagagcca
tatccgggaggaccctgcccctgacctaagcccacccccaaaggccaaactctccactccctcagctcatgcagatctgagtaact
cccaatcttctctctgcagagtccaaatatggtcccccatgcccatgtaaggccaacccagggcctcgcctccagctcaaggcgggacaggt
gccctagagtagcctgcatccagggacaggccccagccgggtgctgacgcatccacctccatctcttcctcagcacctgagttcctgggggggaccatcag
tcttcctgttcccccaaaacccaaggacactctcatgatctcccggaccctcgtggtggacgtgagccaggaagaccccgaggt
ccagttcaactggtacgtggatggcgtgaggaggtgcataatgccaagacaaagccgcgggaggagcagttcaacagcacgtaccgtgtggtcagcgtcctc
accgtcctgcaccaggactggctgaacggcaaggagtacaagtgcaaggtctccaacaaagccctcccgtcctccatcgagaaaaccatctccaaagcca
aaggtgggacccacggggtgcgagggccacatggacagaggtcagctcggcccaccctctgccctgggagtgaccgctgtgccaacctctgtccctacag
ggcagccccgagagccacaggtgtacaccctgcccccatcccaggaggagatgaccaagaaccaggtcagcctgacctgcctggtcaaaggcttctaccc
cagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaagaccacgcctcccgtgctggactccgacggctccttcttcctctac
agcaggctaaccgtggacaagagcaggtggcaggaggggaatgtcttctcatgctccgtgatgcatgaggctctgcacaaccactacacagaagagcc
tctccctgtctctgggtaaa

DNA encoding heavy chain of antibody CA028 496.g3 (including exons but without signal sequence) (SEQ ID NO:24)

gaggttcagctcgttgaatccggaggcggactcgtgcagcctgggggctccttgcggctgagctgcgctgccagtggcttcactttcagcgattacaata
tggcctgggtgcgccaggccccaggcaagggtctggagtgggtggccacaattacctatgagggcagaaacacttattaccgggattcagtgaaagggcg
atttaccatcagcagggataatgcaaagaacagtctgtacctgcagatgaactctctgagagctgaggacaccgctgtctactattgtgcaagcccaccc
cagtactatgagggctcaatctacagattgtggtttgcccattggggccagggaacactggtgaccgtctcgagcgcttctacaaagggcccatcggtct
tccccctggcaccctcctccaagagcacctctgggggcacagcggccctgggctgcctggtcaaggactacttccccgaaccggtgacggtgtcgtggaa
ctcaggcgccctgaccagcggcgtgcacaccttcccggctgtcctacagtcctcaggactctactccctcagcagcgtggtgaccgtgccctccagcagc
ttgggcacccagacctacatctgcaacgtgaatcacaagcccagcaacaccaaggtcgacaagaaagttgagcccaaatcttgtgacaaaactcacacat
gcccaccgtgcccagcacctgaactcctgggggggaccgtcagtcttcctcttcccccaaaacccaaggacaccctcatgatctcccggaccccctgaggt
cacatgcgtggtggtggacgtgagccacgaagaccctgaggtcaagttcaactggtacgtggacggcgtggaggtgcataatgccaagacaaagccgcgg
gaggagcagtacaacagcacgtaccgtgtggtcagcgtcctcaccgtcctgcaccaggactggctgaatggcaaggagtacaagtgcaaggtctccaaca
aagccctcccagcccccatcgagaaaaccatctccaaagccaaagcgcagccccgagaaccacaggtgtacaccctgcccccatcccgggatgagctgac
caagaaccaggtcagcctgacctgcctggtcaaaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaag
accacgcctcccgtgctggactccgacggctccttcttcctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttctcatgct
ccgtgatgcatgaggctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaa

DNA encoding heavy chain of antibody CA028 496.g3 (including signal sequence and exons) (SEQ ID NO:25)

atggaatggtcctgggtcttcctgtttttccttttctgtcacaaccggggtgcacagcgaggttcagctcgttgaatccggaggcggactcgtgcagcctg
ggggctccttgcggctgagctgcgctgccagtggcttcactttcagcgattacaatatggcctgggtgcgccaggccccaggcaagggtctggagtgggt
ggccacaattacctatgagggcagaaacacttattaccgggattcagtgaaagggcgatttaccatcagcagggataatgcaaagaacagtctgtacctg
cagatgaactctctgagagctgaggacaccgctgtctactattgtgcaagcccaccccagtactatgagggctcaatctacagattgtggtttgcccatt
ggggccagggaacactggtgaccgtctcgagcgcttctacaaagggcccatcggtcttccccctggcaccctcctccaagagcacctctgggggcacagc
ggccctgggctgcctggtcaaggactacttccccgaaccggtgacggtgtcgtggaactcaggcgccctgaccagcggcgtgcacaccttcccggctgtc
ctacagtcctcaggactctactccctcagcagcgtggtgaccgtgccctccagcagcttgggcacccagacctacatctgcaacgtgaatcacaagccca
gcaacaccaaggtcgacaagaaagttgagcccaaatcttgtgacaaaactcacacatgcccaccgtgcccagcacctgaactcctgggggggaccgtcagt
cttcctcttcccccaaaacccaaggacaccctcatgatctcccggaccccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtc
aagttcaactggtacgtggacggcgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagcgtcctca
ccgtcctgcaccaggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcgagaaaaccatctccaaagccaa
agcgcagccccgagaaccacaggtgtacaccctgcccccatcccgggatgagctgaccaagaaccaggtcagcctgacctgcctggtcaaaggcttctat
cccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaagaccacgcctcccgtgctggactccgacggctccttcttcctct
acagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttctcatgctccgtgatgcatgaggctctgcacaaccactacacgcagaagag
cctctccctgtctccgggtaaa

cDNA encoding heavy chain of antibody CA028 496.g3 (including signal sequence) (SEQ ID NO:26)

atggaatggtcctgggtcttcctgttttttcctttctgtcacaaccggggtgcacagcgaggttcagctcgttgaatccggaggcggactcgtgcagcctg
ggggctccttgcggctgagctgcgctgccagtggcttcactttcagcgattacaatatggcctgggtgcgccaggccccaggcaagggtctggagtgggt
ggccacaattacctatgagggcagaaacacttattaccgggattcagtgaaagggcgatttaccatcagcagggataatgcaaagaacagtctgtacctg
cagatgaactctctgagagctgaggacaccgctgtctactattgtgcaagcccaccccagtactatgagggctcaatctacagattgtggtttgcccatt
ggggccagggaacactggtgaccgtctcgagcgcttctacaaagggcccatcggtcttccccctggcaccctcctccaagagcacctctgggggcacagc
ggccctgggctgcctggtcaaggactacttccccgaaccggtgacggtgtcgtggaactcaggcgccctgaccagcggcgtgcacaccttcccggctgtc
ctacagtcctcaggactctactccctcagcagcgtggtgaccgtgccctccagcagcttgggcacccagacctacatctgcaacgtgaatcacaagccca
gcaacaccaaggtcgacaagaaagttgagcccaaatcttgtgacaaaactcacacatgcccaccgtgcccagcacctgaactcctgggggggaccgtcagt
cttcctcttccccccaaaacccaaggacaccctcatgatctcccggaccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtc
aagttcaactggtacgtggacggcgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagcgtcctca
ccgtcctgcaccaggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcgagaaaaccatctccaaagccaa
agcgcagccccgagaaccacaggtgtacaccctgcccccatcccgggatgagctgaccaagaaccaggtcagcctgacctgcctggtcaaaggcttctat
cccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaagaccacgcctcccgtgctggactccgacggctccttcttcctct
acagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttctcatgctccgtgatgcatgaggctctgcacaaccactacacgcagaagag
cctctccctgtctccgggtaaa

Human IL-17A (SEQ ID NO:27)

GITIPRNPGCPNSEDKNFPRTVMVNLNIHNRNTNTNPKRSSDYYNRSTSPWNLHRNEDPERYPSVIWEAKCRHLGCINADGNVDYHMNSVPIQQEILVLR
REPPHCPNSFRLEKILVSVGCTCVTPIVHHVA

Human IL-17F (SEQ ID NO:28)

RKIPKVGHTFFQKPESCPPVPGGSMKLDIGIINENQRVSMSRNIESRSTSPWNYTVTWDPNRYPSEVVQAQCRNLGCINAQGKEDISMNSVPIQQETLVV
RRKHQGCSVSFQLEKVLVTVGCTCVTPVIHHVQ

Figure 2: CASPAR criteria

Inflammatory articular disease (joint, spine, or entheseal) AND at least 3 points of the following 5 categories:

Category	Definition	Points
1) Evidence of psoriasis: (Score for 1 of the following[a])		
Current psoriasis	Psoriatic skin or scalp disease present today as judged by a dermatologist or rheumatologist	2 points
Personal history of psoriasis	A history of psoriasis that may be obtained from the subject, family physician, dermatologist, rheumatologist, or other qualified health care provider	1 point
Family history of psoriasis	A history of psoriasis in a first- or second-degree relative according to subject report	1 point
2) Psoriatic nail dystrophy	Typical psoriatic nail dystrophy, including onycholysis, pitting, and hyperkeratosis, observed on current physical examination	1 point
3) A negative test for rheumatoid factor	By any method except latex, but preferably by enzyme-linked immunosorbent assay (ELISA) or nephelometry, according to the local laboratory reference range	1 point
4) Dactylitis: (Score for 1 of the following)		
Current dactylitis	Swelling of an entire digit	1 point
History of dactylitis	A history of dactylitis recorded by a rheumatologist	1 point
5) Radiologic evidence of juxta-articular new bone formation	Ill-defined ossification near joint margins (but excluding osteophyte formation) on plain radiographs of the hand or foot	1 point

CASPAR=Classification Criteria for Psoriatic Arthritis

a "Score for 1 of the following" means that only 1 of the 3 criteria is applicable (either current psoriasis [scores 2 points], personal history [scores 1 point], or family history [scores 1 point]).

Figure 3a: PASI 50/75/90 response at week 8

	Placebo	**UCB4940 80mg/ 40mg/ 40mg**	**UCB4940 160mg/ 80mg/ 80mg**	**UCB4940 240mg/ 160mg/ 160mg**	**UCB4940 560mg/ 320mg/ 320mg**	**UCB4940 Combined 3 top doses group**
Subjects with BSA ≥ 3% psoriasis n (%)	5 (50%)	2 (50%)	4 (67%)	9 (60%)	2 (40%)	15 (58%)
PASI50 n (%) [95% CI]	1 (20%) [4% - 62%]	2 (100%) [34% - 100%]	4 (100%) [51% - 100%]	9 (100%) [70% - 100%]	2 (100%) [34% - 100%]	15 (100%) [80% - 100%]
PASI75 n (%) [95% CI]	0 [0% - 43%]	1 (50%) [10% - 91%]	4 (100%) [51% - 100%]	9 (100%) [70% - 100%]	2 (100%) [34% – 100%]	15 (100%) [80% - 100%]
PASI90 n (%) [95% CI]	0 [0% - 43%]	1 (50%) [10% - 91%]	4 (100%) [51% - 100%]	8 (89%) [57% - 98%]	1 (50%) [10% - 91%]	13 (87%) [62% - 96%]




Figure 3b: Time course of PASI 90-response (PA0007) from first dose(day 0) to day 140 (week 20)

Figure 4: Secukinumab Future 1 Results: PASI (week 24)




Figure 5a: ACR20/50/70 response at week 8

	Placebo (N=12)	**UCB4940 80mg/ 40mg/ 40mg (N=6)**	**UCB4940 160mg/ 80mg/ 80mg (N=6)**	**UCB4940 240mg/ 160mg/ 160mg (N=19)**	**UCB4940 560mg/ 320mg/ 320mg (N=5)**	**UCB4940 Combined 3 top doses group (N=30)**
ACR20 n (%) [95% CI]	2 (17%) [5% - 45%]	3 (50%) [19% - 81%]	5 (83%) [44% - 97%]	15 (79%) [57% - 92%]	4 (80%) [38% - 96%]	24 (80%) [63% - 91%]
ACR50 n (%) [95% CI]	1 (8%) [2% - 35%]	1 (17%) [3% - 56%]	3 (50%) [19% - 81%]	7 (37%) [19% - 59%]	2 (40%) [12% - 77%]	12 (40%) [25% - 58%]
ACR70 n (%) [95% CI]	0 [0% - 24%]	0 [0% - 39%]	0 [0% - 39%]	5 (26%) [12% - 49%]	2 (40%) [12% - 77%]	7 (23%) [12% - 41%]




Figure 5b: Summary Plot of the ACR20 response rates from PA0007 from start of study (day 0) to day 140 (week 20).

Figure 5c: Summary Plot of the ACR50 response rates from PA0007 from start of study (day 0) to day 140 (week 20).




Figure 5d: Summary Plot of the ACR70 response rates from PA0007 from start of study (day 0) to day 140 (week 20).





Figure 6: Secukinumab Future 1 Results and Cimzia RAPID-PsA Results: ACR20

47

ACR20 Response, FUTURE 1 study

- *Results from two different studies are reported, this is not a H2H comparison.*



1. Mease P et al. Arthritis Rheum. 2014; 66(Suppl 11):S423–S424
2. Mease P et al. Ann Rheum Dis. 2014; 73(1):48–55

Figure 7: Summary Table of Bayesian Analysis

Dose Group	N	Observed ACR20	Estimated ACR20	Credible Intervals	
				95%	99%
Placebo	12	16.7%	22%	12% - 36%	9% - 41%
Pooled top doses	30	80.0%	81%	64% - 92%	59% - 94%

Figure 8: Summary Table of ACR20 response at week 8 in psoriatic arthritis for registered anti-TNFs or Phase III results.
Observed ACR20 response rates for registered Anti-TNF's at Week 8 when administered at registered doses

Drug name (Active ingredient)	Active	Placebo	Δ (Difference between active and placebo)	Reference
ANTI-TNF's				
Humira (Adalimumab)	56.7	11.6	45.1	(1)
Simponi (Golimumab)	43.5	8.3	35.2	(2)
Cimzia (Cetrolizumab Pegol)	49.4	22.3	27.1	(3)
ANTI-IL17's				
Cosentyx (Secukinumab)	59.73	21.25	38.5	(4)
ANTI-IL12/23				
Stelara (Ustekinumab)	33.34	20.83	12.51	(5)




Figure 9: Targeted UCB4940 PK concentrations

Figure 9 continued

	Week 0	Week 3	Week 6	Czp (TBC) Trough
Group 1	240 mg	160mg	160 mg	>20 ug/mL
Group 2	160 mg	80 mg	80 mg	> 10 ug/mL
Group 3	560 mg	320 mg	320 mg	> 40 ug/mL
Group 4	80mg	80 mg	80 mg	< 10 ug/mL




Figure 10: Summary PK plot of predicted SC dosing, illustrating that a dose of 320 loading followed by 160mg Q4W or 160 mg Q4W and higher, are able to achieve the plasma concentrations studied in PA0007 at the top 3 doses.




Figure 11: Percent change from baseline in lesional severity score




Figure 12: Percent Change for baseline in PASI

Figure 13:Summary Table of PASI 90 response

Week	PASI90 (%)					
	Placebo N=13	8mg N=4	40mg N=4	160mg N=6	480mg N=6*	640mg N=6
4	0	0	0	3 (50%)	4 (67%)	5 (83%)
6	0	0	0	2 (33%)	5 (83%)	5 (83%)
12	0	0	0	4 (67%)	5 (100%)	5 (83%)

Figure 14: Mean percentage change from baseline in (a) LSS, (b) PASI and (c) PGA in the placebo and bimekizumab cohorts




Figure 15A




Figure 15B




Figure 15C



BMP2
Fold change compared to GM relative expression (GOI/HPRT1)
500
400
300
200
100
0
GFC
GFC(-IL6)
TH-17 SN
IL-17A mAb
IL-17F- mAb
IL-17A/F mAb
TH-17 SN
*
***
***
***

Figure 15D




Figure 15E




Figure 15F




Figure 15G




Figure 16A




Figure 16B

